Journal September 25, 2026 5 min read

Common misconceptions about hepatic steatosis

Hepatic steatosis is fat accumulation in the liver, not a benign finding. This page separates what studies in animals and humans actually show from common assumptions, with research-only framing.

peptides-pro Editorial

What is hepatic steatosis?

Hepatic steatosis is the formal term for fat accumulation in the liver. It is also called fatty liver disease, and in its metabolic context, metabolic dysfunction-associated steatotic liver disease (MASLD). The condition is not a single disease but a histological and clinical spectrum, ranging from simple steatosis to steatohepatitis with inflammation and fibrosis. The evidence block does not provide a sequence, formula, or molecular weight for hepatic steatosis itself, as it is a condition rather than a single molecule.

Research into hepatic steatosis centres on several pathways and receptor families, including the fibroblast growth factor 21 (FGF21)–PPARα axis, the AMP-activated protein kinase (AMPK) pathway, and the GLP-1/GCG receptor dual agonist class.

Research Studies

FGF21 and COX-2-mediated arachidonic acid metabolism in MASLD

In a study using mouse models, FGF21 was identified as a suppressor of hepatic COX-2. Both FGF21 and COX-2 were elevated in steatotic livers, but FGF21 deficiency further increased hepatic COX-2 expression in mice fed a high-fat diet. This led to dysregulated arachidonic acid metabolism, excessive prostaglandin E2 production, aggravated inflammation, and oxidative stress [2]. The findings are from animal and in vitro work; human relevance remains to be established.

Metformin-dapagliflozin and IGF-1 in male T2DM with MASLD

A 3-month, single-center, prospective, randomized, parallel-controlled, open-label trial is investigating the effects of metformin combined with dapagliflozin on serum IGF-1 levels in male patients with type 2 diabetes mellitus (T2DM) and MASLD. Eighty-four eligible male patients (aged 30–60 years, HbA1c 7.0%–10.0%, CAP ≥248 dB/m, on stable metformin monotherapy for ≥8 weeks) will be randomized 1:1 to continue metformin alone or receive metformin plus dapagliflozin 10 mg/day for 12 weeks. The primary endpoint is the change in serum IGF-1 from baseline to 3 months between groups [1]. This study is ongoing; no results are available.

Mazdutide in T2DM and moderate-to-severe NAFLD after semaglutide

A multicenter, prospective, randomized controlled investigator-initiated trial is evaluating the efficacy and safety of switching to mazdutide therapy in patients with T2DM and moderate-to-severe non-alcoholic fatty liver disease (NAFLD) who have achieved glycemic control. The study focuses on Chinese patients with T2DM, who are susceptible to visceral fat accumulation, increasing cardiometabolic risk. The coexistence of T2DM and moderate-to-severe fatty liver significantly elevates liver-related and all-cause risks [3]. This trial is ongoing.

Butyrate or intensive lifestyle modification in type 1 diabetes and MASLD

MASLD is highly prevalent in individuals with type 1 diabetes (T1D) and is associated with increased cardiovascular and metabolic risk. A study aims to evaluate the efficacy of intensive lifestyle modification, butyrate supplementation, or their combination on hepatic steatosis in individuals with T1D and MASLD. Butyrate, a microbiota-derived short-chain fatty acid, has emerged as a potential therapeutic approach because of its anti-inflammatory and metabolic effects [4]. This study is ongoing.

SLC31A1-dependent copper accumulation and AMPKα1 inactivation

In HFD/STZ-induced T2D mice and in glucosamine- or oleic acid-treated hepatocytes, hepatic SLC31A1 expression and copper accumulation were enhanced. This contributed to hepatic glucose and lipid metabolic disturbances through AMPKα1 inactivation [5]. The findings are from animal and in vitro models; human data are not provided.

Pre-hepatectomy rehabilitation with mazdutide in obese MASLD donors

A study is evaluating a 12-week prehabilitation strategy combining mazdutide (a GLP-1/GCG receptor dual agonist) with lifestyle optimization versus lifestyle optimization alone in potential living liver transplantation donors with metabolic dysfunction-associated steatohepatitis (MASLD). Overweight or obese individuals temporarily disqualified due to hepatic steatosis will be randomized 1:1 to mazdutide subcutaneous injection once weekly plus standardized care or lifestyle optimization alone [6]. This trial is ongoing.

Tirzepatide and liver fat changes by PNPLA3 I148M genotype

In the SURPASS-3 MRI substudy, tirzepatide significantly reduced liver fat content (LFC) versus insulin degludec in insulin-naïve patients with T2DM and MASLD. A post hoc analysis evaluated changes in MRI-assessed LFC and cardiometabolic parameters by presence (genotypes GG and CG) or absence (genotype CC) of the PNPLA3 I148M allele after 52-week treatment. Tirzepatide-treated participants experienced significant reductions in LFC [7]. This analysis is from a completed trial; the influence of the PNPLA3 I148M allele on LFC changes was assessed.

CoQ10 and liver fat in mitochondrial diabetes mellitus

A prospective study aims to evaluate the effect of 12-week CoQ10 supplementation (300 mg/day) on liver fat content (assessed by FibroTouch CAP) in patients with mitochondrial diabetes mellitus (MDM) with the m.3243A>G mutation. An exploratory case-control design will compare baseline characteristics among MDM patients, type 1 diabetes patients, and healthy controls. This study is the first to explore the link between mitochondrial defects and hepatic fat accumulation [8]. This trial is ongoing.

Comparison of study designs and populations

Study	Population	Intervention	Primary outcome	Status
NCT07778719 [1]	Male T2DM with MASLD	Metformin + dapagliflozin vs metformin alone	Change in serum IGF-1	Ongoing
NCT07713992 [3]	T2DM with moderate-to-severe NAFLD	Mazdutide switch	Efficacy and safety	Ongoing
NCT07684248 [4]	T1D with MASLD	Butyrate, lifestyle, or combination	Hepatic steatosis	Ongoing
NCT07718126 [6]	Obese MASLD living liver donors	Mazdutide + lifestyle vs lifestyle alone	Efficacy and safety	Ongoing
NCT07748130 [8]	MDM with m.3243A>G mutation	CoQ10 300 mg/day	Liver fat content (FibroTouch CAP)	Ongoing

If you are reading this for personal health reasons

The compounds and interventions described here are sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.